Company
Headquarters: Salt Lake City, UT, United States
Employees: 330
CEO: Dr. Christopher C. Gibson Ph.D.
$2.19 Billion
USD as of Jan. 1, 2026
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.
| Last Financial Reports Date | Sept. 30, 2025 |
| Revenue TTM | $43.7 M |
| EBITDA | $-637,875,968 |
| Gross Profit TTM | $-503,448,000 |
| Profit Margin | 22.65% |
| Operating Margin | -3327.58% |
| Quarterly Revenue Growth | -80.20% |
Recursion Pharmaceuticals, Inc. has the following listings and related stock indices.
Stock: NASDAQ: RXRX wb_incandescent